The content of protoanemonin, a known biologically active constituent of Clematis spp., was determined by GC-MS in the leaf, stem and root extracts of one Chinese species and four Australian Clematis taxa. The results showed that protoanemonin concentrations varied between different plants and that leaves contained higher concentrations than stems and roots. To our knowledge this is the first study to determine protoanemonin content variation in leaf, stem and root of Clematis spp.
Protoanemonin, a volatile constituent of Clematis spp. [1a] , has antifungal and antibacterial activities [1b-d] . Protoanemonin is liberated enzymatically from a glucosidic precursor, ranunculin, and can polymerize to anemonin [2] . These three compounds have cytotoxic effects against tumour cell lines of the NCI 60 tumor panel (National Cancer Institute Cancer Screen Current Data, 2009 ). Anemonin has anti-inflammatory effects through inhibition of iNOS-mediated NO signalling elicited by LPS stimulation [3a] . The protoanemonin content of the leaves of several Clematis spp. [3b] has been studied, but the content in stem and root have not been well described for any Clematis spp.
We investigated the protoanemonin content of leaf, stem and root of one Chinese Clematis species and four Australian Clematis taxa (Table 1) . Protoanemonin is a steam-volatile compound that after isolation readily polymerizes in the course of a few days [2] . The steam distilled extract of C. montana was extracted with CH 2 Cl 2 and portions of this solution, evaporated to dryness, yielded 11.6 ± 0.05 mg/mL of viscous liquid. GC-MS analysis of the original extract showed the presence of >95% of one volatile compound, having a mass spectrum consistent with that of protoanemonin [3c] .
Protoanemonin content of leaf, stem and root:
The lowest content of protoanemonin was in C. montana stem and root (0.06% and 0.08%, respectively), which was less than half of that in all the other species. The sources of protoanemonin with the greatest concentration were the leaf of C. gentianoides and C. aristata (W) (0.72% and 0.71%, respectively). There appears to be some differentiation in the content of protoanemonin within a single plant between different plant parts. For example, C. gentianoides leaf contained more than four times that of the root. This implies some difference in ranunculin and/or protoanemonin biosynthesis, transport and/or biotransformation within the plant. The protoanemonin content of plant parts differed between the species examined. That of C. aristata (N) and C. aristata (W) leaf differed more than threefold (0.19 % vs. 0.71 %, respectively), but a similar difference was not observed in the roots and stems. Our study revealed that the protoanemonin concentration varied between different plants parts and between species. However, the factors that contributed to this variation were not studied in this investigation. These data show for the first time that protoanemonin is present Table 1 : Percentage of protoanemonin in Clematis spp. fresh material (mean ± SD; n=3).
Protoanemonin in fresh material
0.50 ± 0.09 0.52 ± 0.09 0.24 ± 0.04 a : C. aristata narrow leaf form; b : C. aristata wide leaf form throughout Clematis spp. plants, including the roots, stems and leaves. The protoanemonin mean concentrations in leaves of C. aristata and C. gentianoides in this investigation were higher than those reported by Southwell and Tucker (0.62% and 0.55%, respectively) [3b]. This difference could be caused by the use of sonication in the present study, resulting in more complete extraction; or the different origin of the plants. The protoanemonin content of the four Australian Clematis taxa seems higher than that in C. montana, which is used in TCM. This could be due to a real interspecies difference. There is, to our knowledge, no data available regarding the protoanemonin content of the herbal preparation "chuan mu tong", that is prepared from the stems of C. montana. Stems of C. montana are used in TCM for arthritis, urinary tract infection and mastitis [4] . Our results showed that the protoanemonin content of C. montana stem (0.06%) is lower than that of the leaf (0.31%) and root (0.08%). This suggests that protoanemonin is not the major therapeutic constituent of C. montana.
The root is the plant part that is most utilized in these preparations, with almost two thirds of them containing root, but half containing only the root. By comparison, only about 5% of the preparations consist purely of leaf. This suggests that leaf is the plant part of Clematis spp. least utilized in TCM. The leaf appears, from the results of the current study, to contain the highest concentration of protoamenonin, compared with stems and roots. Although protoanemonin is a biologically active constituent, based on this study it is suggested that this is not the most important potential therapeutic agent in the TCM preparations that incorporate various plant tissues used in preparations are summarized in Table 2 [4] . In recent years, a number of studies have also found that Clematis spp. extracts have antimicrobial [5a,b] , anticancer [6a,b] , analgesic [6c,7] and antimalarial activities [8a] . Clematis species native to Australia have been used in traditional medical practices in the treatment of cold and headache [8b]. The Australian Clematis taxa used in this study, including Clematis 'Garden Surprise', a new hybrid of C. aristata and C. gentianoides, contained protoanemonin in leaf, stem and root in amounts higher than those in the Chinese Clematis sp. These results provide basic data for further phytochemical research on Clematis spp. used in TCM and Clematis spp. of Australian and other origins. The factors that contributed to this variation are possibly worth investigation. 
Experimental

Extraction and isolation of protoanemonin:
The method for the extraction and determination of protoanemonin from Clematis spp. was based on that described by Southwell and Tucker [3b], with slight modifications. C. montana fresh leaves and stems (371 g) were hydrodistilled for 3 h. The condensate was extracted with 50 mL CH 2 Cl 2 . The extract was dried over anhydrous MgSO 4 . Five 2.00 mL aliquots of this solution were evaporated to dryness and weighed to determine the concentration of protoanemonin in solution. A portion of this extract (400 µL) was mixed with 400 µL of a solution of linalool in CH 2 Cl 2 (1 mg/mL) and analyzed by GC-MS for determination of the response factor of protoanemonin with respect to linalool. Clematis plants were separated into leaf, stem and root. Fresh plant material (0.50 g) in up to 3 replicates was extracted with ethanol (2.00 mL) containing linalool (1.00 mg/mL) as internal standard at room temperature for 23 h, and then sonicated for 0.5 h, decanted and analyzed by GC-MS.
Gas chromatography-mass spectrometry: GC-MS was performed using a Varian 3800 GC connected to a Varian 1200 triple quadrupole mass spectrometer. The column was 30 m x 0.25 mm diameter, 0.25 micron film VF5-ms. A Varian 1177 injector was used in split mode (30:1). The carrier gas (helium) flow rate was 1.5 mL/min in constant flow mode; the injection temperature was 180°C. GC oven temperature was from 70°C to 150°C at 20°C per minute and peaks were observed at m/z (%); 96 (100), 68 (48), 54 (31), 42 (73), together with the internal standard, linalool. The calculated GC-MS response factor for protoanemonin with respect to linalool was 0.363.
